louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00710749: The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Official title: An Open Prospective Multicenter Study Comparing the Urine Flow Measurements of Standard Clinic Flow Measurements vs Comercially Available Portable Digital Flow Meters and a Disposable Flow Meter in a Crossover and Randomized Order on Male BPH Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bladder Outlet Obstruction
Lower Urinary Tract Symptoms
Keywords: Lower urinary tract symptoms leading to lower flow rates
Lead sponsor: Wellspect HealthCare
Sponsor class: INDUSTRY
First posted: 2008-07-04
Enrollment: 60
Sex: MALE
Minimum age (years): 45
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary flow than a single measurement performed in the clinic.


Eligibility criteria: Inclusion Criteria:

* Provision of informed consent
* Males aged 45-85 years
* \>60% of the voiding volume is above 100 ml per voiding verified by a urinary diary
* Able to read write and understand given instructions

Exclusion Criteria:

* Patients practicing CIC
* Ongoing symptomatic UTI
* Known Neurological Disease that is affecting the bladder function
* Known past or present alcohol or drug abuse
* Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
* Previous enrolment or randomisation of treatment in the present study.
* Suspected poor compliance based on less than 80 % compliance to voiding diary
* Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
* On alpha-blocker or 5-alpha reductase inhibitor treatment, treatment started less than 2 months prior to enrolment
* Clinic flow below 100 ml

Primary outcomes:
measure: Mean Urine Flow Rate
timeFrame: At every voiding event during approximately one week.
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: David Geffen school of Medicine at UCLA, Department of Urology
state: California
city: Nijmegen
country: Netherlands
facility: UMC ST Radboud Nijmegen, Department of Urology
city: Warsaw
country: Poland
facility: Klinika Urology, Akademi Medycznej
city: Swansea
country: United Kingdom
facility: Clinical Research Unit, Morriston Hospital, Swansea NHS Trust
Study officials:
affiliation: Dentsply Sirona Implants and Consumables
name: Magnus Jacobsson, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT05694949: Main Postoperative Complications After COVID-19
Official title: Main Postoperative Complications After SARS-CoV-2 Infection: A Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intestines Cancer
Pulmonary Cancer
Liver Cancer
Trauma
Fractures, Bone
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Anhui Medical University
name: First Affiliated Hospital of Chongqing Medical University
name: Sichuan Academy of Medical Sciences
name: Second Hospital of Shanxi Medical University
First posted: 2023-01-23
Enrollment: 100000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients having elective or confine surgery in operating room

Brief summary: To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.


Eligibility criteria: Inclusion Criteria:

* Age≥18 years;
* Patients undergoing any type of elective or confine surgery in operating room;
* Informed consent.

Exclusion Criteria:

* Surgery under local anesthesia (without participation of anesthetist)
* Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc
* Patients who cannot determine whether they have had SARS CoV-2 infection before surgery
* Participating in conflicting clinical study

Primary outcomes:
measure: All-cause mortality at 30 days after operation
timeFrame: 30 days after surgery
Secondary outcomes:
measure: Main pulmonary complications at 30 days after operation
timeFrame: 30 days after surgery
measure: Major Adverse Cardiovascular Events (MACE)
timeFrame: 30 days after surgery
Other outcomes:
Locations:
Study officials:
affiliation: Renji Hospital, Shanghai Jiaotong University, School of Medcine
name: Diansan Su, MD,PHD
role: STUDY_CHAIR
References:
Clinical trial NCT03019549: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
Official title: Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Eli Lilly and Company
First posted: 2017-01-12
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected.

Participants will be on study for 21 days with a follow-up at least 7 days afterwards.

Screening will be undertaken within 45 days prior to enrollment.


Eligibility criteria: Inclusion Criteria:

* Women not of childbearing potential may participate and include those who are:

  * Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or
  * Postmenopausal - defined as women over 50 years of age with an intact uterus who have not taken hormones or oral contraceptives within 1 year, who have had either Spontaneous cessation of menses for at least 12 consecutive months, or 6 to 12 months of spontaneous amenorrhea with follicle-stimulating hormone level greater than (\>)40 milli-international units per millilitre (mIU/mL) consistent with menopause
* Caucasian and may be of Hispanic ethnicity
* Body mass index (BMI) of 19 to 32 kilogram per meter square (kg/m²), inclusive, at the time of screening

Exclusion Criteria:

- Have a clinically significant abnormal blood pressure or heart rate (supine) as determined by the investigator

Primary outcomes:
measure: Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin
timeFrame: 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose
Secondary outcomes:
measure: Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)
timeFrame: Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose
measure: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat
timeFrame: .Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose
Other outcomes:
Locations:
city: Daytona Beach
country: United States
facility: Covance Clinical Research Inc
state: Florida
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00307749: Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
Official title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetic Polyneuropathy
Keywords: Neuropathy
Nerve Conduction
Lead sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor class: INDUSTRY
First posted: 2006-03-28
Enrollment: 420
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy

Detailed description: The study will use a double-blind, randomized, placebo-controlled, fixed-dose, parallel-group design. Patients will be randomized equally to 1 of 4 treatment groups: MCC-257 20 mg, MCC-257 40 mg, MCC-257 80 mg, or placebo, given once daily for 24 weeks. The study will consist of 2 periods: 1) a screening period of up to 21 days prior to baseline, including a formal screening visit; and 2) a 24-week treatment period, during which patients will take the study treatment, and have various assessments performed during 4 visits.

Eligibility criteria: Inclusion Criteria:

* The patient is male or female, 18-70 years of age
* The patient has either type 1 or type 2 diabetes
* The patient has mild to moderate diabetic neuropathy
* The patient is free from other clinically significant illness or disease, as determined by medical history, physical examination, laboratory evaluations, and other safety tests

Exclusion Criteria:

* Being treated with anticoagulants other than aspirin, such as warfarin, digoxin, Plavix
* BMI\>40
* A significant disorder or a condition other than diabetes that can cause symptoms or physical conditions that mimic peripheral neuropathy or interfere with cognition
* Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma potentially affecting nerve function
* Women of childbearing potential who do not refrain from sexual activity or use adequate contraception
* Pregnant or lactating women
* An ALT or AST value \>2X upper limit of normal (ULN)
* Clinically significant cardiovascular disease within the last six (6) months

Primary outcomes:
measure: Nerve Conduction Studies
timeFrame: Day 1, Week 24
Secondary outcomes:
measure: Nerve fiber density
timeFrame: Day 1, Week 24
measure: QST
timeFrame: Day 1, Week 12, Week 24
measure: Symptom
timeFrame: Day 1, Week 12, Week 24
measure: Clinical Global Impression
timeFrame: Week 12, Week 24
Other outcomes:
Locations:
Study officials:
affiliation: Information at Mitsubishi Pharma America
name: Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05532449: Dezoxide Suppresses Sufentanil-induced Cough
Official title: Low-dose Dezoxide Suppresses Sufentanil-induced Cough During Induction of General Anesthesia in Patients Undergoing Cardiac Surgery: a Prospective, Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sufentanil-induced Cough
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2022-09-08
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Dizocine (0.03 mg/kg) or saline followed by sufentanil 0.4ug/kg was administered, and induction was completed with 3 min of observation. Heart rate and mean arterial pressure (MAP) were recorded before induction of anesthesia, before and 1 min after intubation, and side effects during induction, such as vomiting, hypoxemia (SpO2 \<90%), or other expected effects. The number of coughs was recorded in both groups, and the severity of cough was defined as follows: mild, 1-2 coughs; moderate, 3-4 coughs; severe, 5 or more coughs.


Eligibility criteria: Inclusion Criteria:

* Patients admitted for elective valve surgery, artificial vessel replacement or coronary artery bypass graft surgery; Age 18\~80 years old; Sex is not limited; ASA class II\~III; NYHA Class II-III; Patients or their family members have signed the clinical trial informed consent form

Exclusion Criteria:

* Upper respiratory tract infection within the last two weeks; Long history of smoking; chronic obstructive pulmonary disease; Highly reactive airway diseases such as bronchitis and asthma; Presence of high cranial pressure, high eye pressure, pulmonary alveolus; Malignant tumor, hematological disease, severe liver and kidney dysfunction, recent serious infection, etc.

Primary outcomes:
measure: sufentanil-induced cough
timeFrame: 2 minutes after intubation
Secondary outcomes:
measure: heart rate
timeFrame: 2 minutes after intubation
measure: mean arterial pressure
timeFrame: 2 minutes after intubation
measure: SpO2
timeFrame: 2 minutes after intubation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01466049: New Biomarkers Evaluating Ovarian Cancer
Official title: Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adnexal Mass
Keywords: Ovarian Cancer
Adnexal Mass
Pelvic Mass
Lead sponsor: Fujirebio Diagnostics, Inc.
Sponsor class: INDUSTRY
First posted: 2011-11-06
Enrollment: 280
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with an adnexal mass, presenting to a general surgeon or obstetrician/ gynecologist at a general or specialty center within the United States, for whom a decision to proceed with surgery to remove the mass has been made.

Brief summary: The purpose of this study is to evaluate new biomarkers for patients presenting to a physician for surgery to remove a mass in their pelvis and to continue to evaluate these types of patients using the ROMA algorithm for post-market benefits.


Eligibility criteria: Inclusion Criteria:

* Female, age 18 years or older
* Adnexal mass present documented by imaging
* Scheduled to undergo surgery based on a finding of adnexal mass
* Able and willing to provide Informed Consent

Exclusion Criteria:

* Previous history of ovarian cancer
* Previous history of bilateral oophorectomy
* Currently known to be pregnant
* Unable to provide informed consent

Primary outcomes:
measure: Evaluate novel biomarkers for patients with an adnexal mass
timeFrame: observational studies
Secondary outcomes:
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: New Hanover Regional Medical Center
state: North Carolina
city: Oklahoma City
country: United States
facility: University of Oklahoma
state: Oklahoma
Study officials:
affiliation: Fujirebio Diagnostics, Inc.
name: Diana Dickson
role: STUDY_DIRECTOR
References:
Clinical trial NCT01391949: Pedaling Exercises for Disability and Activity Limitations
Official title: UCFit Pedaling Exercises to Limit Disability in the Outpatient Setting
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Stroke
Keywords: disability
walking
feedback
exercise
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2011-07-12
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This purpose of this study is to determine the effect of different levels of feedback on participation in a home exercise regimen and the amount of walking performed by patients recently discharged from the acute rehabilitation setting.

Detailed description: The UCFit (University of California's U Cycle to Fitness) device is a standard commercial arm and leg restorator modified to collect pedaling data and to transmit it wirelessly to a central database, allowing for remote exercise monitoring. In this study, patients with stroke will perform pedaling exercise on the UCFit device prior to and then for a period of twelve weeks after discharge to home from inpatient rehabilitation. Differing levels of feedback will be provided to study subjects and corresponding changes in the amount of pedaling and walking performed will be identified. The results of this study will offer insight into the activity levels of disabled persons in their home environments. Furthermore, it will help in the identification of strategies that can increase activity levels in the critical period after discharge to home.

Eligibility criteria: Inclusion Criteria:

* diagnosis of stroke
* no major contraindications to participating in light-to-moderate exertion
* able to follow and retain verbal directions to carry out simple lower extremity repetitive exercises
* planned discharge to home with family available to assist

Exclusion Criteria:

* pre-morbid limitations in walking related to another medical disease
* body mass index \>30
* fractures or contractures that prevent use of an extremity for pedaling
* impairment in cognition that precludes a full understanding of the risks and benefits of this study

Primary outcomes:
measure: Walking speed
timeFrame: three months
Secondary outcomes:
measure: Distance walked in 3 minutes
timeFrame: three months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Andrew Dorsch, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, Los Angeles
name: Bruce Dobkin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02149849: Surgical Positioning of the Arm During Thoracic Surgery -Effect on Shoulder Pain After Surgery?
Official title: Lateral Surgical Positioning for Thoracic Surgery -Effect on Ipsilateral Shoulder Pain?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Cancer
Keywords: Ipsilateral shoulder pain
Surgical positioning
Lung cancer
Thoracotomy
Video assisted thoracic surgery
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2014-05-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Up to 85% experience shoulder pain after thoracic surgery, especially on the same side as surgery are performed. Referred phrenic nerve pain is probably one cause of ipsilateral shoulder pain (ISP), and positioning of the arm during surgery another. Studies indicates that ISP can be caused by the positioning of the patient during surgery due to muscle -and ligament strain. Can a change in the surgical positioning (less press and stretch) of the ipsilateral arm effect the shoulder pain after thoracic surgery?


Eligibility criteria: Inclusion Criteria:

* Men and women;18 years and older
* Thoracotomy for lung cancer
* Video assisted thoracic surgery for lung cancer.

Exclusion Criteria:

* Received treatment for shoulder pain
* Use pain medication on regular basis
* Under 18 year
* Length of stay in ICU more than 24 hours after surgery
* Does not understand the native language

Primary outcomes:
measure: Postoperative shoulder pain after lung surgery.
timeFrame: 3 months
Secondary outcomes:
measure: Pain medication
timeFrame: 3 months
measure: White blood cell
timeFrame: 3 months
measure: C reactive protein
timeFrame: 3 months
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital
name: Stein O Danielsen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01489449: Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
Official title: Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Heart Disease
NSTEMI
Keywords: drug coated balloon
NSTEMI
Lead sponsor: Universität des Saarlandes
Sponsor class: OTHER
First posted: 2011-12-09
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI.

Detailed description: The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R) Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI. Primary efficacy endpoint will be MACE (cardiac mortality, reinfarction, and target lesion revascularization) after 9 months.

Eligibility criteria: Inclusion Criteria:

* NSTEMI with
* Ischemic symptoms (angina pectoris) \> 30 minutes
* Last symptoms within 72 hours before randomization
* Positive cardiac troponin T, I, or hs-Troponin above 99th percentile
* age \> 18 years
* Identifiable culprit lesion without angiographic evidence of large thrombus with intended early PCI (treatment of up to two lesions allowed)

Exclusion Criteria:

* Cardiogenic shock
* ST-elevation myocardial infarction
* No identifiable culprit lesion, Indication for acute bypass surgery
* Comorbidity with limited life expectancy \< 9-12 months
* Contraindication for treatment with heparin, ASA and thienopyridines

Primary outcomes:
measure: MACE
timeFrame: 9 months
Secondary outcomes:
measure: Stent thrombosis (ARC
timeFrame: 9 months, 3 years, 5 years
measure: Mortality (cardiac and non-cardiac)
timeFrame: 9 months, 3 years, 5 years
measure: Reinfarction
timeFrame: 9 months, 3 years, 5 years
measure: target lesion revascularization
timeFrame: 9 months, 3 years, 5 years
measure: target vessel revascularization
timeFrame: 9 months, 3 years, 5 years
measure: any revascularization
timeFrame: 9 months, 3 years, 5 years
Other outcomes:
Locations:
city: Homburg/Saar
country: Germany
facility: Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
state: Saarland
Study officials:
affiliation: Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
name: Bruno Scheller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04301349: Dinoprostone vs Misoprostol Before LNG-IUD Insertion
Official title: Comparative Study Between Vaginal Dinoprostone and Vaginal Misoprostol Prior to IUD Insertion in Multiparous Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: IUD Insertion Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-03-10
Enrollment: 200
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of this study is to compare the safety and efficacy of vaginal dinoprostone vs vaginal misoprostol administration prior to IUD insertion in multiparous women regarding reduction in iud insertion pain


Eligibility criteria: Inclusion Criteria:

* multiparous women requesting IUD insetion

Exclusion Criteria:

* active genital infection,uterine anomalies, and contraindication or allergy to dinoprostone or misoprostol

Primary outcomes:
measure: pain during IUD insertion: visual analog scale
timeFrame: 2 minutes
Secondary outcomes:
measure: duration of IUD insertion
timeFrame: 5 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Cairo University
name: AHMED SAMY
role: PRINCIPAL_INVESTIGATOR
References: